Array BioPharma (ARRY) : During the past 4 weeks, traders have been relatively bearish on Array BioPharma (ARRY), hence the stock is down -10.84% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.19% relative to the S&P 500. The 4-week change in the price of the stock is -10.5% and the stock has fallen -8.22% in the past 1 week.
Array BioPharma Inc. has dropped 2.11% during the last 3-month period . Year-to-Date the stock performance stands at -23.22%. The stock has recorded a 20-day Moving Average of 15.09% and the 50-Day Moving Average is 10.98%.
Array BioPharma (NASDAQ:ARRY): The stock opened at $3.44 on Friday but the bulls could not build on the opening and the stock topped out at $3.45 for the day. The stock traded down to $3.23 during the day, due to lack of any buying support eventually closed down at $3.24 with a loss of -6.90% for the day. The stock had closed at $3.48 on the previous day. The total traded volume was 3,191,784 shares.
Also, In the latest statement by the brokerage house, Stifel Nicolaus maintains its outlook on Array BioPharma (NASDAQ:ARRY). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm raises the price target from $7 per share to $8 per share. The rating by the firm was issued on August 5, 2016.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.